South Australian clinician-scientist Professor Jamie Craig has been named in The Ophthalmologist Power List for 2026.

The Power List showcases ophthalmology leaders and influencers who have made a significant impact in the field in the past 12–18 months.

Prof Craig is Director of the Flinders Centre for Ophthalmology, Eye and Vision Research; and Chair and Academic Head of the Department of Ophthalmology, Flinders University College of Medicine and Public Health in South Australia. He was named South Australian Scientist of the Year in 2024.

Prof Craig has led the development of SightScore, a polygenic risk score for glaucoma, including the incorporation of a start-up company Seonix Bio, to facilitate fundraising activities to fund regulatory accreditation in Australia, New Zealand, and the United States.

The test has now been launched in those countries and is being used by leading ophthalmologists to assist with key clinical decision making around initiation and escalation of treatment in glaucoma suspects and cases.

References available at mivision.com.au.

This year’s Power List was headed by Professor Gus Gazzard, from Moorfields Eye Hospital NHS and University College London, in the United Kingdom.

Prof Gazzard said his work has been “increasingly focused on improving how we might conduct randomised controlled trials (RCTs) in ophthalmology”.

Visit: shopaus.tsklab.com.

“Without RCTs, which preserve the glorious power of randomisation to give us robust answers, we fall prey to bias, selective reporting and ulterior motives,” Prof Gazzard told The Ophthalmologist .

Accurate clinical documentation one of the most time-consuming aspects of modern ophthalmic practice, with multiple measurements, imaging findings, medications, and management decisions critical for patient care.

In response, many clinicians are exploring the use of ‘ambient’ artificial intelligence (AI) scribes – systems that transcribe clinician- patient conversations and generate structured medical notes.

Recognising the importance of rigorous evaluation, i-scribe, an AI documentation platform, has placed clinical research at the centre of its development strategy, conducting specialty-specific studies to assess the real-world performance of AI scribes in ophthalmology.

Unlike many technology solutions developed primarily outside clinical practice, i-scribe was founded by a team that includes practising ophthalmologists and clinicians. Their clinical experience helped shape the early development of the platform, with the goal of creating a documentation tool that reflects the practical realities of ophthalmology consultations.

In collaboration with i-scribe, and with the aim of refining AI documentation capabilities, researchers from Monash Health, Department of Otolaryngology, Head and Neck Surgery and Monash University Department of Surgery analysed recordings from 26 real-world ophthalmology consultations, conducted with patient consent. To ensure a fair comparison, three AI scribe systems, including i-scribe and two competing platforms, were tested under identical conditions.

TSK Laboratory International, manufacturer of premium needles and cannulas, has launched direct operations in Australia and New Zealand.

Until now, practitioners across Australia and New Zealand have relied on a network of medical wholesalers to procure TSK’s needles and cannulas, which include Steriject, the Invisible Needle, and its Low Dead Space (LDS) technology, which minimises the space within the syringe-hub assembly, preventing air bubbles and reducing waste of sight-saving biologics. The launch of direct operations effectively centralises and streamlines this supply chain through a dedicated, localised e-commerce platform.

TSK, which has based its operations in Macquarie Park, Sydney, said ophthalmic professionals will benefit from product authenticity, a more resilient supply chain, and highly transparent, competitive pricing.

Reference available at mivision.com.au.